EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer

Yingqi Xu iD, Hao Ji iD, Yidan Zhang, Liwen Xiong, Baohui Han, Hua Zhong, Jianlin Xu, Runbo Zhong iD

The Oncologist · 05.07.2024 · 29 (7) · e932-e940

DOI: 10.1093/oncolo/oyae052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 25.03.2024. Verfasst von Yingqi Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's R…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Lung Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Innovation program of Shanghai, Beijing Xisike Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of neoadjuvant treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy in patients with stage III-N2 EGFR-mutant remains unsatisfactory. This study explored the potential benefits of combining first-generation EGFR-TKI with chemotherapy as a neoadjuvant treatment for patients with stage III-N2 EGFR-mutant non-small cell lung cancer (NSCLC). Patients and Methods The medical records of patients with III-N2 EGFR-mutant NSCLC who received neoadjuvant therapy with EGFR-TKI at Shanghai Chest Hospital from October 2011 to October 2022 were retrospectively reviewed. Patients with stage III-N2 EGFR-mutant NSCLC who received first-generation TKI combined with chemotherapy as neoadjuvant treatment were included in the combination group, and those who received EGFR-TKI monotherapy were included in the monotherapy group. The study assessed the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, disease-free survival (DFS), overall survival (OS), downstaging rates of pathologic lymph nodes (from stage N2 to N1 or N0), major pathologic response (MPR) rate, pathological complete response (PCR) rate, and safety.

Results

A total of 74 631 patients with EGFR-mutant NSCLC were screened, and 60 patients were included, 7 of whom did not undergo surgery after neoadjuvant targeted therapy. Of the remaining 53 patients, 15 received first-generation EGFR-TKI combined with chemotherapy as neoadjuvant treatment, and 38 received EGFR-TKI monotherapy. The median follow-up time was 44.12 months. The ORR was 50.0% (9/18) in the combination group and 40.5% (17/42) in the monotherapy group (P = .495). The MPR rate was 20.0% (3/15) and 10.5% (4/38) in the combination and monotherapy groups, respectively (P = .359). No patients achieved PCR in the combination group, while 3 (7.89%) attained PCR in the monotherapy group. The 2 groups did not differ in N2 downstaging rate (P = .459). The median DFS was not reached in the combination group, while it was 23.6 months (95% CI: 8.16-39.02) in the monotherapy group (P = .832). Adverse events observed were consistent with those commonly associated with the 2 treatments.

Conclusion

Combination therapy with first-generation EGFR-TKI and chemotherapy could be considered a neoadjuvant treatment option for patients with stage III-N2 EGFR-mutant NSCLC, exhibiting acceptable toxicity. However, regarding short-term efficacy, combination therapy did not demonstrate superiority over EGFR-TKI monotherapy. Long-term follow-up is warranted for a more accurate assessment of the DFS and OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsNeoadjuvant TherapyProtein Kinase InhibitorsNeoplasm StagingMutationHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAdultAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

EGFRNSCLCTKIchemotherapyneoadjuvant treatment

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
  • Department of Respiratory and Critical Care Medicine, Department of Healthcare-Associated Infection Management, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of C…

ORCID-Profile: Yingqi Xu, Hao Ji, Runbo Zhong

Förderung

  • Science and Technology Innovation program of Shanghai
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Xu, Y., Ji, H., Zhang, Y., Xiong, L., Han, B., Zhong, H., Xu, J., & Zhong, R. (2024). Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer. The Oncologist, 29(7), e932-e940. https://doi.org/10.1093/oncolo/oyae052

Vancouver

Xu Y, Ji H, Zhang Y, Xiong L, Han B, Zhong H, et al. Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer. The Oncologist. 2024;29(7):e932-e940. doi:10.1093/oncolo/oyae052

BibTeX
@article{Xu2024,
  author = {Xu, Yingqi and Ji, Hao and Zhang, Yidan and Xiong, Liwen and Han, Baohui and Zhong, Hua and Xu, Jianlin and Zhong, Runbo},
  title = {Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {7},
  pages = {e932--e940},
  doi = {10.1093/oncolo/oyae052}
}
Kostenlos starten →